Physician profile
Basil Abdo
NPI 1730121443
$3,823.23
in general payments reported to CMS, 2019-2025
20 companies · $506 in 2025
The $506 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $220 · 2020: $656 · 2021: $616 · 2022: $536 · 2023: $591 · 2024: $698 · 2025: $506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,795.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,795.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $755.74 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $650.85 | 2019-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $520.88 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Pfizer INC. | $445.09 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $402.31 | 2020-2025 | Fasenra, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $284.86 | 2019-2025 | Jardiance |
| Exact Sciences Corporation | $130.83 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $95.34 | 2019-2024 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $87.60 | 2020-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Esperion Therapeutics, INC. | $85.97 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $81.31 | 2020-2022 | |
| Abbott Laboratories | $80.91 | 2021-2023 | Freestyle Libre 2 |
| Stimwave Technologies Incorporated | $57.13 | 2019 | |
| Shield Therapeutics INC | $32.19 | 2024 | |
| Axsome Therapeutics, INC. | $31.98 | 2025 | Auvelity |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $21.60 | 2022 | |
| Genentech USA, INC. | $15.47 | 2020 | |
| Inari Medical, INC. | $14.91 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Sanofi-Aventis U.S. LLC | $14.52 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Basil Abdo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.